- Home
- APLM vs ELAB Comparison
APLM vs ELAB Comparison
Compare APLM & ELAB Stocks: Price Trends, ML Decisions, Charts, Trends, Technical Analysis and more.
- Machine Learning Prediction
- ML Decision
- APLM
- ELAB
- Stock Information
- Founded
- APLM 2016
- ELAB 2020
- Country
- APLM United States
- ELAB United States
- Employees
- APLM N/A
- ELAB N/A
- Industry
- APLM Blank Checks
- ELAB
- Sector
- APLM Finance
- ELAB
- Exchange
- APLM Nasdaq
- ELAB Nasdaq
- Market Cap
- APLM 7.7M
- ELAB 6.6M
- IPO Year
- APLM N/A
- ELAB 2023
- Fundamental
- Price
- APLM $6.71
- ELAB $4.42
- Analyst Decision
- APLM Strong Buy
- ELAB
- Analyst Count
- APLM 2
- ELAB 0
- Target Price
- APLM $425.00
- ELAB N/A
- AVG Volume (30 Days)
- APLM 42.6K
- ELAB 410.3K
- Earning Date
- APLM 04-15-2025
- ELAB 05-14-2025
- Dividend Yield
- APLM N/A
- ELAB N/A
- EPS Growth
- APLM N/A
- ELAB N/A
- EPS
- APLM N/A
- ELAB N/A
- Revenue
- APLM $2,101,000.00
- ELAB N/A
- Revenue This Year
- APLM N/A
- ELAB N/A
- Revenue Next Year
- APLM N/A
- ELAB N/A
- P/E Ratio
- APLM N/A
- ELAB N/A
- Revenue Growth
- APLM 70.54
- ELAB N/A
- 52 Week Low
- APLM $6.20
- ELAB $3.88
- 52 Week High
- APLM $63.00
- ELAB $1,064.00
- Technical
- Relative Strength Index (RSI)
- APLM 43.33
- ELAB 34.30
- Support Level
- APLM $6.20
- ELAB $4.08
- Resistance Level
- APLM $8.00
- ELAB $4.73
- Average True Range (ATR)
- APLM 1.37
- ELAB 0.85
- MACD
- APLM -0.18
- ELAB 0.25
- Stochastic Oscillator
- APLM 9.44
- ELAB 8.31
About APLM Apollomics Inc.
Apollomics Inc is an innovative clinical-stage biopharmaceutical company focused on the discovery and development of oncology therapies with the potential to be combined with other treatment options to harness the immune system and target specific molecular pathways to inhibit cancer. The company lead programs include vebreltinib (APL-101), a potent, selective c-Met inhibitor for the treatment of non-small cell lung cancer and other advanced tumors with c-Met alterations, and uproleselan (APL-106), a specific E-Selectin antagonist that has the potential to be used adjunctively with standard chemotherapy to treat acute myeloid leukemia.
About ELAB Elevai Labs Inc.
PMGC Holdings Inc advancing in Medical Aesthetics and Biopharmaceutical Innovation. It specializes in Skin Aesthetics, Obesity, and Metabolic Health business.